September 3, 2020 -- Enesi Pharma is partnering with the University of Adelaide to develop a new thermostable, solid-dose DNA vaccine for Zika virus.
The vaccine will be developed using Enesi's ImplaVax platform to create a DNA vaccine in a solid-dose implant format for transcutaneous delivery via a needle-free device. The novel DNA vaccine construct was developed by researchers at the University of Adelaide. This combination is expected to enhance the vaccine's efficacy, thermal stability and allow for safe, rapid vaccination of target populations that are geographically and economically disadvantaged.
The collaboration, valued at $1 million, will advance the development of the thermostable, solid-dose Zika virus DNA vaccine to a phase I clinical trial.
The program is being funded by the Australian government's Biomedical Translation Bridge, Enesi Pharma, the Hospital Research Foundation, Adelaide Enterprise Commercial Accelerator Scheme, and the University of Adelaide Faculty of Health and Medical Sciences.
Copyright © 2020 scienceboard.net